B
Baylx
Focuses on the development of stem cell therapeutics for different diseases
About Baylx
Baylx Inc. is a clinical-stage biopharmaceutical company specializing in the development of stem cell therapeutics derived from human umbilical cord tissue. The company focuses on addressing significant unmet medical needs in areas such as autoimmune diseases, liver disease, and advanced cancers. Baylx's core technology involves the use of mesenchymal stem cells (MSCs) from umbilical cord tissue, which offers several advantages over MSCs derived from other adult tissues, including a non-invasive donor procedure, robust proliferation, high scalability, and superior biological activities.
Baylx serves a diverse range of clients, including medical researchers, healthcare providers, and pharmaceutical companies. The company operates in the biopharmaceutical market, leveraging its proprietary technologies to manufacture clinical-grade, off-the-shelf MSCs. Baylx's business model revolves around developing and testing its stem cell-based product candidates in FDA-regulated clinical trials, aiming to bring innovative treatments to market. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Irvine, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 23.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Oncology, Stem Cells, Regenerative Medicine, Spinout, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2022 | $41M | $165M | SDIC Venture Capital · Nanjing Jiangbei New Area Sci-Tech Investment Group · Huajin Capital | ↗ |
| SPINOUT✓Other financing | Jan 2015 | $0 | — | University of California, Irvine | — |
Growth signals
Latest recorded traffic for Baylx is 80 monthly website visits, down 66.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Huajin Capital
SDIC Venture Capital- NGNanjing Jiangbei New Area Sci-Tech Investment Group
Other known investors1 additional known investor
University of California, Irvine
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Baylx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Baylx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.